These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19966803)

  • 1. A restricted spectrum of NRAS mutations causes Noonan syndrome.
    Cirstea IC; Kutsche K; Dvorsky R; Gremer L; Carta C; Horn D; Roberts AE; Lepri F; Merbitz-Zahradnik T; König R; Kratz CP; Pantaleoni F; Dentici ML; Joshi VA; Kucherlapati RS; Mazzanti L; Mundlos S; Patton MA; Silengo MC; Rossi C; Zampino G; Digilio C; Stuppia L; Seemanova E; Pennacchio LA; Gelb BD; Dallapiccola B; Wittinghofer A; Ahmadian MR; Tartaglia M; Zenker M
    Nat Genet; 2010 Jan; 42(1):27-9. PubMed ID: 19966803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects.
    Runtuwene V; van Eekelen M; Overvoorde J; Rehmann H; Yntema HG; Nillesen WM; van Haeringen A; van der Burgt I; Burgering B; den Hertog J
    Dis Model Mech; 2011 May; 4(3):393-9. PubMed ID: 21263000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
    Aoki Y; Niihori T; Banjo T; Okamoto N; Mizuno S; Kurosawa K; Ogata T; Takada F; Yano M; Ando T; Hoshika T; Barnett C; Ohashi H; Kawame H; Hasegawa T; Okutani T; Nagashima T; Hasegawa S; Funayama R; Nagashima T; Nakayama K; Inoue S; Watanabe Y; Ogura T; Matsubara Y
    Am J Hum Genet; 2013 Jul; 93(1):173-80. PubMed ID: 23791108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.
    Tartaglia M; Pennacchio LA; Zhao C; Yadav KK; Fodale V; Sarkozy A; Pandit B; Oishi K; Martinelli S; Schackwitz W; Ustaszewska A; Martin J; Bristow J; Carta C; Lepri F; Neri C; Vasta I; Gibson K; Curry CJ; Siguero JP; Digilio MC; Zampino G; Dallapiccola B; Bar-Sagi D; Gelb BD
    Nat Genet; 2007 Jan; 39(1):75-9. PubMed ID: 17143282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibromatosis-Noonan syndrome: case report and clinicopathogenic review of the Neurofibromatosis-Noonan syndrome and RAS-MAPK pathway.
    Reig I; Boixeda P; Fleta B; Morenoc C; Gámez L; Truchuelo M
    Dermatol Online J; 2011 Apr; 17(4):4. PubMed ID: 21549079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
    Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
    BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRAS associated RASopathy and embryonal rhabdomyosarcoma.
    Garren B; Stephan M; Hogue JS
    Am J Med Genet A; 2020 Jan; 182(1):195-200. PubMed ID: 31697451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.
    Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H
    Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
    Motta M; Fidan M; Bellacchio E; Pantaleoni F; Schneider-Heieck K; Coppola S; Borck G; Salviati L; Zenker M; Cirstea IC; Tartaglia M
    Hum Mol Genet; 2019 Mar; 28(6):1007-1022. PubMed ID: 30481304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
    Lee ST; Ki CS; Lee HJ
    Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype and phenotype spectrum of NRAS germline variants.
    Altmüller F; Lissewski C; Bertola D; Flex E; Stark Z; Spranger S; Baynam G; Buscarilli M; Dyack S; Gillis J; Yntema HG; Pantaleoni F; van Loon RL; MacKay S; Mina K; Schanze I; Tan TY; Walsh M; White SM; Niewisch MR; García-Miñaúr S; Plaza D; Ahmadian MR; Cavé H; Tartaglia M; Zenker M
    Eur J Hum Genet; 2017 Jun; 25(7):823-831. PubMed ID: 28594414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
    Tidyman WE; Rauen KA
    Curr Opin Genet Dev; 2009 Jun; 19(3):230-6. PubMed ID: 19467855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular disease in Noonan syndrome.
    Pierpont ME; Digilio MC
    Curr Opin Pediatr; 2018 Oct; 30(5):601-608. PubMed ID: 30024444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
    Cavé H; Caye A; Ghedira N; Capri Y; Pouvreau N; Fillot N; Trimouille A; Vignal C; Fenneteau O; Alembik Y; Alessandri JL; Blanchet P; Boute O; Bouvagnet P; David A; Dieux Coeslier A; Doray B; Dulac O; Drouin-Garraud V; Gérard M; Héron D; Isidor B; Lacombe D; Lyonnet S; Perrin L; Rio M; Roume J; Sauvion S; Toutain A; Vincent-Delorme C; Willems M; Baumann C; Verloes A
    Eur J Hum Genet; 2016 Aug; 24(8):1124-31. PubMed ID: 26757980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.
    Molzan M; Schumacher B; Ottmann C; Baljuls A; Polzien L; Weyand M; Thiel P; Rose R; Rose M; Kuhenne P; Kaiser M; Rapp UR; Kuhlmann J; Ottmann C
    Mol Cell Biol; 2010 Oct; 30(19):4698-711. PubMed ID: 20679480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autism traits in the RASopathies.
    Adviento B; Corbin IL; Widjaja F; Desachy G; Enrique N; Rosser T; Risi S; Marco EJ; Hendren RL; Bearden CE; Rauen KA; Weiss LA
    J Med Genet; 2014 Jan; 51(1):10-20. PubMed ID: 24101678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome.
    Cordeddu V; Yin JC; Gunnarsson C; Virtanen C; Drunat S; Lepri F; De Luca A; Rossi C; Ciolfi A; Pugh TJ; Bruselles A; Priest JR; Pennacchio LA; Lu Z; Danesh A; Quevedo R; Hamid A; Martinelli S; Pantaleoni F; Gnazzo M; Daniele P; Lissewski C; Bocchinfuso G; Stella L; Odent S; Philip N; Faivre L; Vlckova M; Seemanova E; Digilio C; Zenker M; Zampino G; Verloes A; Dallapiccola B; Roberts AE; Cavé H; Gelb BD; Neel BG; Tartaglia M
    Hum Mutat; 2015 Nov; 36(11):1080-7. PubMed ID: 26173643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Noonan syndrome phenotype associated with a germline Q71R MRAS variant: a recurrent substitution in RAS homologs in various cancers.
    Suzuki H; Takenouchi T; Uehara T; Takasago S; Ihara S; Yoshihashi H; Kosaki K
    Am J Med Genet A; 2019 Aug; 179(8):1628-1630. PubMed ID: 31173466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
    Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
    Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.